BR112018012201A2 - ?micropartículas carregadas com ciclosporina de liberação sustentada? - Google Patents

?micropartículas carregadas com ciclosporina de liberação sustentada?

Info

Publication number
BR112018012201A2
BR112018012201A2 BR112018012201A BR112018012201A BR112018012201A2 BR 112018012201 A2 BR112018012201 A2 BR 112018012201A2 BR 112018012201 A BR112018012201 A BR 112018012201A BR 112018012201 A BR112018012201 A BR 112018012201A BR 112018012201 A2 BR112018012201 A2 BR 112018012201A2
Authority
BR
Brazil
Prior art keywords
sustained release
loaded microparticles
pharmaceutical formulation
microparticles
release cyclosporin
Prior art date
Application number
BR112018012201A
Other languages
English (en)
Other versions
BR112018012201B1 (pt
Inventor
Paice Dewi
Bamsey Katharine
Thomas Nigel
Seaman Paul
Original Assignee
Midatech Pharma Wales Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midatech Pharma Wales Ltd filed Critical Midatech Pharma Wales Ltd
Publication of BR112018012201A2 publication Critical patent/BR112018012201A2/pt
Publication of BR112018012201B1 publication Critical patent/BR112018012201B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

é provida uma formulação farmacêutica de liberação controlada, compreendendo micropartículas carregadas com ciclosporina de um polímero bioreabsorvível compreendendo poli (d, l-lactídeo), em que o diâmetro médio das micropartículas está no intervalo de 20µm a 40µm. são também providos usos médicos da formulação farmacêutica, em particular no tratamento de uveíte, um processo para a produção da formulação farmacêutica e formas de dosagem injetáveis, incluindo aquelas formuladas para injeção intravítrea.
BR112018012201-7A 2015-12-18 2016-12-16 Micropartículas carregadas com ciclosporina de liberação sustentada BR112018012201B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522441.3 2015-12-18
GBGB1522441.3A GB201522441D0 (en) 2015-12-18 2015-12-18 Sustained release cyclosporine-loaded microparticles
PCT/EP2016/081593 WO2017103218A1 (en) 2015-12-18 2016-12-16 Sustained release cyclosporine-loaded microparticles

Publications (2)

Publication Number Publication Date
BR112018012201A2 true BR112018012201A2 (pt) 2018-11-27
BR112018012201B1 BR112018012201B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
JP6894436B2 (ja) 2021-06-30
JP2019503352A (ja) 2019-02-07
US20190054023A1 (en) 2019-02-21
AU2016372554A1 (en) 2018-06-14
KR20180094944A (ko) 2018-08-24
CN108472247A (zh) 2018-08-31
US11154504B2 (en) 2021-10-26
GB201522441D0 (en) 2016-02-03
ES2782111T3 (es) 2020-09-10
CA3008491A1 (en) 2017-06-22
AU2016372554B2 (en) 2021-12-23
EP3389626A1 (en) 2018-10-24
EP3389626B1 (en) 2020-01-29
CN108472247B (zh) 2022-05-24
WO2017103218A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
BR112017018318A2 (pt) composição farmacêutica para tratar câncer compreendendo microrna como ingrediente ativo
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
BR112018010671A2 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
AR105223A1 (es) Compuestos químicos
BR112017009510A2 (pt) composições compreendendo ciclosporina
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2015001574A1 (es) Terapia combinada para el cancer
MX2016011236A (es) Dispersiones solidas de bendamustina e infusion continua.
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
BR112018012201A2 (pt) ?micropartículas carregadas com ciclosporina de liberação sustentada?
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
SV2016005308A (es) Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
AR097179A1 (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
CL2015003702A1 (es) Formulación farmacéutica en forma de micropartículas estériles, que comprenden como agente activo rhein, y copolímeros del ácido láctico y glicólico (plga). proceso de elaboración y uso en pacientes que presentan patologías articulares.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2016, OBSERVADAS AS CONDICOES LEGAIS